Fat Necrosis / Good to Excellent Cosmesis
Anywhere in breast / Outside tumor bed
Oschner Clinic2 / 150 / 3.8 / 1.3%(crude) / 1.3%(crude) / Not Reported / Grade III: 2.7%
Fat Necrosis: Not reported separately / 75%
NIO, Budapest1* phase I/II / 45 / 6.7 / 4.4% (5 yrs)
9% (7 yrs) / 4.4% (5yrs)
9% (7 yrs) / 0% / Grade III: 2.2%
Fat Necrosis: 22% / 84%
NIO Budapest3Phase III / 126 / 3.0 / 2.3% (crude) / 1.2% (crude) / Not Reported / Grade II/III: 3%
Fat Necrosis: Not Reported / 86%
William Beaumont4,5 / 199 / 6.3 / 1.7% (5 yrs)
5.3% (10yrs) / 1.5% / 1%( 5yrs)
7.5% (10yrs) / Grade III:1%
Fat Necrosis: 11% / 99%
VirginiaCommonwealth University1* / 59 / 4.2 / 5.1% (5yrs) / 2.6% (5yrs) / 0% / Score 3: 9%
Fat Necrosis: 2.2% / 79%
Orbero1* / 49 / 4.6 / 4% (crude) / 2% (crude) / Not Reported / Not Reported / Not Reported
RTOG 9517 phase II6,7 / 99 / 6.1 / HDR 3% (5 yrs)
LDR 6% (5yrs) / 1% (5 yrs)
1% (5 yrs) / 2% (5 yrs)
6% (5 yrs) / Grade III–IV: 18% LDR, 6% HDR
Fat Necrosis: 0% / Not Reported
German Austrian Group8 / 274 / 2.6 / 0.7% (3 yrs) / 0.3% (3yrs) / Nil / Grade III: 1.0–4.7%
Fat Necrosis: 4.7% / 94%
University of Wisconsin9 / 240 / 2.5 / 1.4%(crude rate) / 1.4%
(crude rate) / Not Reported / Fat Necrosis: 9% / 97%
All Mature Series / 1,241 / 2.5–6.7 / 0.7–9.0% / 0.3–9.0% / 0–7.5% / Grade III/IV: 1–18%
Fat Necrosis:0–22% / 75–99%
Table 1 Results of APBI using quality assured LDR or HDR interstitial implants in optimally selected patients.
*Adapted from Sarin R (2005) Partial-breast treatment for early breast cancer: emergence of a new paradigm. Nat Clin Pract Oncol 2:40–47